| Ytd | -39.02% | |
| 1y | -34.47% |
| Open | 2.10 | Prev Close | 2.11 | Low | 2.10 | High | 2.11 | Mkt Cap | 34.34M |
| Vol | 1.16K | Avg Vol | 275.00K | EPS | -0.57 | P/E | -3.70 | Forward P/E | -2.90 |
| Beta | 0.39 | Short Ratio | 3.25 | Inst. Own | 21.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 06-20 | 50-d Avg | 2.33 | 200-d Avg | 3.17 | 1yr Est | 10.44 |
GRCE News
Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Cli
Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report)'s share price fell 2.5% on Wednesday. The
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 ST
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigat
ATLANTA, June 03, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Grace Thera
Grace Therapeutics is rated a Speculative Buy with a $4 price target, implying 57% upside after a sh
LOS ANGELES--(BUSINESS WIRE)---- $GRCE--GRCE Investors Have Opportunity to Join Grace Therapeutics,
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics,
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Grace Therapeutics Inc. (NASDAQ:GRCE) shares are down during Friday's premarket session following a
Grace Therapeutics said on Thursday the U.S. Food and Drug Administration declined to appro
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, an
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace T
Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report) was the recipient of a significant increas
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace T